Whole-genome sequencing of fathers with children with developmental disorders shows sperm mutation burden indistinguishable from controls.
This cohort study evaluated the transmissible de novo disease risk in fathers of children with developmental disorders compared to population reference cohorts. The analysis included 168 parent-child trios, with sperm sequencing performed on 127 fathers. Researchers utilized whole-genome sequencing of parent-child trios and ultra-accurate duplex sequencing of paternal sperm to assess mutation profiles.
The primary finding indicated that sperm mutation burden and mutational spectra were indistinguishable from those observed in the population reference cohorts. While the global dN/dS metric was 1.56 (95% CI 1.45-1.67) in fathers versus 1.44 (95% CI 1.17-1.77) in controls, the overall mutational load remained comparable. Additionally, 28 of 32 significantly selected genes overlapped with prior findings, reinforcing consistency with existing data.
Regarding specific variant types, early mosaic variants were harbored in 6 of 127 fathers. The allele fractions for these variants ranged from 0.7% to 14.8%. Notably, these early mosaic variants accounted for only approximately 11% of the aggregated exome pathogenic burden. No adverse events, discontinuations, or tolerability issues were reported, as this was a genetic sequencing study without pharmacological intervention.
Key limitations include the observational nature of the cohort design and the specific selection of fathers with children already diagnosed with developmental disorders. The study did not report follow-up data or specific funding conflicts. Clinicians should interpret these results as observational associations rather than causal links, acknowledging that the presence of early mosaic variants does not significantly elevate transmissible risk in this context.